相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer
Antonino Musolino et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy
Xin Chen et al.
FRONTIERS IN IMMUNOLOGY (2019)
The Influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
T. Magnes et al.
PHARMACOGENOMICS JOURNAL (2018)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update
Sharon H. Giordano et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
Nadine Norton et al.
BREAST CANCER RESEARCH (2018)
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
Aura Muntasell et al.
FRONTIERS IN IMMUNOLOGY (2017)
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/ HER2-Positive Breast Cancer Analysis of the NSABP B-31 Trial
Patrick G. Gavin et al.
JAMA ONCOLOGY (2017)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Y. J. Bang et al.
ANNALS OF ONCOLOGY (2017)
Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel
Noelia Martinez-Janez et al.
BREAST CARE (2016)
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
Keith L. Knutson et al.
CANCER RESEARCH (2016)
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
A. Musolino et al.
PHARMACOGENOMICS JOURNAL (2016)
Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy
E. Muraro et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review
Diogo Mendes et al.
BREAST CANCER RESEARCH (2015)
Incidence, Risk Factors, and Management of Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab
Lisa M. Thompson et al.
ONCOLOGIST (2014)
Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831
Nadine Norton et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Can Immunity to Breast Cancer Eliminate Residual Micrometastases?
Mary L. Disis et al.
CLINICAL CANCER RESEARCH (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians
Raffaella Palumbo et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2013)
Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
Sara A. Hurvitz et al.
CLINICAL CANCER RESEARCH (2012)
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O. Persky et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Augmented HER-2-Specific immunity during treatment with trastuzumab and chemotherapy
Clare Taylor et al.
CLINICAL CANCER RESEARCH (2007)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
分享论文
